Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 29;99(22):e20438.
doi: 10.1097/MD.0000000000020438.

Hyaluronic acid predicts poor prognosis in breast cancer patients: A protocol for systematic review and meta analysis

Weiping Wu  1   2 , Lifen Chen  1   2 , Yanzhong Wang  1 , Jing Jin  1   2 , Xinyou Xie  1 , Jun Zhang  1
Affiliations

Hyaluronic acid predicts poor prognosis in breast cancer patients: A protocol for systematic review and meta analysis

Weiping Wu et al. Medicine (Baltimore). .

Abstract

Background: Hyaluronic acid (HA) may be a novel prognostic biomarker of breast cancer. However, the available evidence is controversial. Therefore, we performed a meta-analysis to determine the prognostic role of HA in breast cancer.

Methods: The data were extracted from seven articles by searching the databases of PubMed, EMBASE, Web of Science, the Chinese National Knowledge Infrastructure and Wanfang data for the prognostic role of HA in breast cancer. In reference to survival outcomes, the pooled hazard ratios (HRs) of HA were calculated given a 95% confidence interval (CI).

Results: A total of seven articles were included in our study involving 2664 cases. The result of meta-analysis showed that a high HA level predicts poor overall survival (OS) (HR = 1.86, 95% CI: 1.28-2.71, P = .001) and shortened disease-free or recurrence-free survival or progression free survival (DFS/RFS/PFS) (HR = 1.63, 95% CI: 1.14-2.33, P = .007) in breast cancer patients. Moreover, a high HA level in stroma (HR = 1.63, 95% CI: 1.06-2.51, P = .025) and plasma (HR = 3.26, 95% CI: 2.25-4.73, P < .001) significantly predicted poor OS. Besides, a tendency shows that HA was significantly correlated with lymph node metastasis (HR = 1.55, 95% CI: 0.96-2.49, P = .070) and tumor grade (HR = 2.10, 95% CI: 0.89-4.96, P = .089) on the clinical characteristics of patients.

Conclusion: These results suggested that HA has a potential to be prognostic biomarker in breast cancer patients, especially location in stroma and plasma.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of included study.
Figure 2
Figure 2
The pooled HR of HA for overall survival and disease-free survival of breast cancer.
Figure 3
Figure 3
The pooled HR of HA for overall survival of breast cancer by subgroup analysis.
Figure 4
Figure 4
The pooled OR of HA for lymph node metastasis and tumor grade of breast cancer.
Figure 5
Figure 5
The publication bias was evaluated through Egger's tests.
Figure 6
Figure 6
Sensitivity analysis for OS (A) and DFS/RFS/PFS (B).
See this image and copyright information in PMC

References

    1. Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524–48. - PMC - PubMed
    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29. - PubMed
    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917. - PubMed
    1. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977–1010. - PMC - PubMed
    1. Wallwiener M, Hartkopf AD, Baccelli I, et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013;137:503–10. - PubMed